Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

European Partners to Seek New Approaches for Dealing with Colorectal Cancer

By BiotechDaily International staff writers
Posted on 26 Dec 2013
Print article
A European research project is directed at finding new diagnostic and therapeutic tools to better find and treat patients with colorectal cancer.

Colorectal cancer (CRC) is the third most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the second most common cause of cancer death. More than half of all CRC patients develop distant metastases and have five-year overall survival of less than 5% because of ineffective treatments.

A six million euro research project on CRC funded by the European Commission's Framework VII Program called MErCuRIC is linked to a thousand-patient multicenter phase Ib/II clinical trial. Experiments have been designed to assess a novel therapeutic strategy that combines treatment with the MEK inhibitor PD-0325901 (MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells) and the MET (an oncogene that encodes hepatocyte growth factor receptor) inhibitor PF-02341066. It is expected that the combined treatment will combat metastasis, improve survival, and change current clinical practice for CRC patients with KRAS mutant (MT) and KRAS wild type (WT) (with aberrant c-MET) tumors.

The MErCuRIC research project, which comprises 13 partners in eight different European countries, will go beyond the current state-of-the- art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.

Dr. Sandra van Schaeybroeck, professor of medicine at Queen's University (Belfast, United Kingdom), said, "Our research has identified two key genes that are contributing to the aggressive spread of colorectal cancer. The research being carried out by MErCuRIC will allow us to bring this research to the next level by developing and conducting a clinical trial that targets the products of these two genes in patients with metastic or aggressive colorectal cancer."

Dr. Tim Maughan, professor of clinical oncology at the University of Oxford (United Kingdom), said, "This is an important study, which has the potential to develop new approaches to treat patients who have what is essentially an incurable disease. Bringing together world leading researchers from across Europe has the potential to make important developments in the war against this very aggressive form of cancer."

Related Links:

MErCuRIC
Queen's University
University of Oxford



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.